GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » Beneish M-Score

Cosmo Pharmaceuticals NV (XSWX:COPN) Beneish M-Score : -2.89 (As of Dec. 12, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.89 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Cosmo Pharmaceuticals NV's Beneish M-Score or its related term are showing as below:

XSWX:COPN' s Beneish M-Score Range Over the Past 10 Years
Min: -3.16   Med: -2.2   Max: 3.95
Current: -2.89

During the past 13 years, the highest Beneish M-Score of Cosmo Pharmaceuticals NV was 3.95. The lowest was -3.16. And the median was -2.20.


Cosmo Pharmaceuticals NV Beneish M-Score Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Beneish M-Score Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.05 -2.08 -2.29 -2.11 -2.89

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.11 - -2.89 -

Competitive Comparison of Cosmo Pharmaceuticals NV's Beneish M-Score

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Pharmaceuticals NV's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Beneish M-Score falls into.



Cosmo Pharmaceuticals NV Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cosmo Pharmaceuticals NV for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7057+0.528 * 1.0241+0.404 * 1.371+0.892 * 0.8685+0.115 * 0.9434
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.6747+4.679 * -0.069596-0.327 * 0.1858
=-2.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was CHF26.8 Mil.
Revenue was CHF87.5 Mil.
Gross Profit was CHF69.7 Mil.
Total Current Assets was CHF96.4 Mil.
Total Assets was CHF522.4 Mil.
Property, Plant and Equipment(Net PPE) was CHF27.0 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF13.4 Mil.
Selling, General, & Admin. Expense(SGA) was CHF5.1 Mil.
Total Current Liabilities was CHF24.3 Mil.
Long-Term Debt & Capital Lease Obligation was CHF0.9 Mil.
Net Income was CHF-4.7 Mil.
Gross Profit was CHF0.0 Mil.
Cash Flow from Operations was CHF31.7 Mil.
Total Receivables was CHF43.8 Mil.
Revenue was CHF100.7 Mil.
Gross Profit was CHF82.2 Mil.
Total Current Assets was CHF302.1 Mil.
Total Assets was CHF749.6 Mil.
Property, Plant and Equipment(Net PPE) was CHF29.9 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF13.7 Mil.
Selling, General, & Admin. Expense(SGA) was CHF3.5 Mil.
Total Current Liabilities was CHF192.4 Mil.
Long-Term Debt & Capital Lease Obligation was CHF1.7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(26.834 / 87.499) / (43.784 / 100.748)
=0.306678 / 0.434589
=0.7057

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(82.232 / 100.748) / (69.735 / 87.499)
=0.816215 / 0.796981
=1.0241

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (96.407 + 26.961) / 522.445) / (1 - (302.076 + 29.879) / 749.614)
=0.763864 / 0.557165
=1.371

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=87.499 / 100.748
=0.8685

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(13.674 / (13.674 + 29.879)) / (13.449 / (13.449 + 26.961))
=0.313962 / 0.332814
=0.9434

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(5.095 / 87.499) / (3.503 / 100.748)
=0.058229 / 0.03477
=1.6747

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.888 + 24.25) / 522.445) / ((1.748 + 192.385) / 749.614)
=0.048116 / 0.258977
=0.1858

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-4.651 - 0 - 31.709) / 522.445
=-0.069596

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cosmo Pharmaceuticals NV has a M-score of -2.89 suggests that the company is unlikely to be a manipulator.


Cosmo Pharmaceuticals NV Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV Headlines

No Headlines